Press Release

CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced the summary results of a poster presentation from the on-going preclinical partnership with the H. Lee Moffitt Cancer Center & Research Institute (“Moffitt”) showing preclinical data from the company’s unique delivery approach that unlocks the powerful effects of …

Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting Read More »

CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, …

Dyve Announces Poster Presentation at 2023 AACR Annual Meeting Read More »

CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that Tatyana Beldock has joined Dyve’s Board of Directors. Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are thrilled to have Tatyana join our Board. Tatyana brings a wealth of business, investment, and strategic experience to our …

Dyve Biosciences Appoints Tatyana Beldock to Board of Directors Read More »

When: November 14, 2022Where: Philadelphia, PATopic: “The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study”.  Presented by Dr. Puja Khanna, the study provides evidence of systemic pH modulation demonstrated as part of our TARGETS …

Dyve’s TARGETS Phase 2 Study Abstract Presented at ACR Read More »

When: October 24 and 25, 2022  Where: Boston, MATopic: “Targeting TME Acidity and Turbocharging Immunotherapy with Novel Drug Delivery” We are excited to share how Dyve’s patented emulsion chemistry delivers a broad range of molecules never before possible, turning the skin tissue into a tunable drug delivery portal for locally optimized or systemic delivery. 

CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Chuck Harbert, Ph.D., Chief Scientific Officer of Dyve and additional members of management will be attending the Biotechnology Innovation Organization (BIO) Annual Convention …

Dyve Biosciences to Participate in the BIO International Convention Read More »

Topical application allowing transdermal delivery of DYV702 at the site of the affected joint significantly reduced pain intensity and duration of acute gout flare with higher overall response rates, faster time to resolution, improvements in physical function and reduction in rescue medication use CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), …

Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress Read More »

CAMARILLO, Calif., May 04, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Ryan Beal, M.D., Chief Executive Officer and Co-founder, will be presenting a corporate overview at the UBS Global Healthcare Conference taking place at …

Dyve Biosciences to Present at the UBS Global Healthcare Conference Read More »

CAMARILLO, Calif., March 09, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Ryan Beal, M.D., Chief Executive Officer and Co-founder, will be participating in a fireside chat at the 34th Annual Roth Conference in Dana …

Dyve Biosciences to Present at the 34th Annual Roth Conference Read More »

– Former Array BioPharma and Pfizer Executive Joins Dyve Biosciences – CAMARILLO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal drug delivery technology to a broad pipeline of clinical assets, today announced the appointment of Nicholas A. Saccomano, Ph.D., a seasoned biopharmaceutical professional with nearly …

Dyve Biosciences Announces the Appointment of Nicholas A. Saccomano, Ph.D., to its Scientific Advisory Board Read More »